Molecular characterization of early precursor lesions of pancreatic ductal adenocarcinoma

The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms with the aim to investigate the existence of particular activated pathways and/or similar immunological mutations. It is interesting to note that two neoplasms shared a common mutation ofthe B7-H3 gene, with the consecutive impairment of its expressed protein. In both PDAC and NSCLC, the expression of this protein was associated with a worse survival rate. Since B7-H3 is an anti-apoptotic protein, the reduction of its expression or function should justify a pro-apoptotic activity with a leading justification of the long survival of the patient considered in this report.

Download Full-text

Molecular characterization of cellular heterogeneity in pancreatic ductal adenocarcinoma by transcriptome profiling

Pancreatology ◽

10.1016/j.pan.2021.05.198 ◽

2021 ◽

Vol 21 ◽

pp. S74

Author(s):

P. Di Chiaro ◽

S. Brandini ◽

G. Diaferia ◽

G. Natoli

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Molecular Characterization ◽

Transcriptome Profiling ◽

Cellular Heterogeneity ◽

Ductal Adenocarcinoma

Download Full-text

Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

10.20944/preprints201905.0173.v1 ◽

2019 ◽

Author(s):

Oronzo Brunetti ◽

Giuseppe Badalamenti ◽

Simona De Summa ◽

Angela Calabrese ◽

Antonella Argentiero ◽

...

Keyword(s):

Lung Cancer ◽

Pancreatic Ductal Adenocarcinoma ◽

Molecular Characterization ◽

Progression Free Survival ◽

Critical Issue ◽

Ductal Adenocarcinoma ◽

Multiple Primary Cancers ◽

Second Line ◽

Oncology Practice

Management of multiple primary cancers, a not so infrequent event in oncology practice, is a critical issue due to the lack of literature . In this study, we reported the case of a patient with metachronous double metastatic non small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. She achieved a progression free survival and an overall survival (OS) of 28 months for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapies treatments displayed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms with the aim to investigate the existence of particular activated pathways and/or similar immunological mutations. it is interesting to note that two neoplasms shared a commune mutation of B7-H3 gene, with the consecutive impairment of its expressed protein. In both PDAC and NSCLC, the expression of this protein was associated with a worse survival. Since B7-H3 is an anti-apoptotic protein, the reduction of its expression or function should justify a pro-apoptotic activity with a putative justification of the long survival of the patient considered in this report.

Download Full-text

Omics Approaches in Pancreatic Adenocarcinoma

Cancers ◽

10.3390/cancers11081052 ◽

2019 ◽

Vol 11 (8) ◽

pp. 1052

Author(s):

Iranzu González-Boja ◽

Antonio Viúdez ◽

Saioa Goñi ◽

Enrique Santamaria ◽

Estefania Carrasco-García ◽

...

Keyword(s):

Pancreatic Cancer ◽

Survival Rate ◽

Pancreatic Ductal Adenocarcinoma ◽

Ductal Adenocarcinoma ◽

Curative Intent ◽

Pancreatic Cancers ◽

Wide Range ◽

Prevention And Treatment ◽

Shed Light

Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients.

Download Full-text